Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes

Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2003-08, Vol.26 (8), p.2400-2404
Hauptverfasser: LARSEN, Jakob R, SJOHOLM, Hans, HANSSEN, Kristian F, SANDVIK, Leiv, BERG, Tore J, DAHL-JORGENSEN, Knut
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2404
container_issue 8
container_start_page 2400
container_title Diabetes care
container_volume 26
creator LARSEN, Jakob R
SJOHOLM, Hans
HANSSEN, Kristian F
SANDVIK, Leiv
BERG, Tore J
DAHL-JORGENSEN, Knut
description Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen 1 2 1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway 2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway 3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway 4 Endocrinology Department, Aker University Hospital, Oslo, Norway 5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no Abstract OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration. RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years (range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower limbs was assessed at baseline, after 8 years, and after 18 years. RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude (NAPA) at the last examination were significantly associated with mean HbA 1c ( P < 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P < 0.01). The number of nerves with NCV ( P < 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol, microalbuminuria, or smoking. CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c
doi_str_mv 10.2337/diacare.26.8.2400
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_infotracgeneralonefile_A107199684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A107199684</galeid><sourcerecordid>A107199684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</originalsourceid><addsrcrecordid>eNptks-KFDEQxoMo7jj6AF4kCHoQesyfTndyXGfdVVjcPayIp5BOV89k6UnGpFvZm2ffwNfzSUw7DQsy5FCh-H31FVWF0HNKVozz-m3rjDURVqxayRUrCXmAFlRxUQhRyodoQWipCqEUO0FPUrolhJSllI_RCWVSMlmpBfp1tR_czvT4XR9Ciy_60YYEeB38EEOPz8bo_AZTib-CiQlfR0gQv0P-QXT7LcQs_TRl8Pno7eCCx87jazM48EPCX9ywxZwc1H9-_p4Kmn9U6PDN3R4wxWfONDBAeooedaZP8GyOS_T5_P3N-kNxeXXxcX16WVhB1FAAa-tKUC46bktmOmFo1aiyYXVHjajLWtJairqqFa1Nw6WlTBnTtq0hTUt4w5fo9aHuPoZvI6RB71yy0PfGQxiTrnkpGMkOS_TyP_A2jNHn3jRjnDBFRZWh4gBtTA_a-S4M0dgN-Gk0wUPncvqUkpoqVcky86sjfH4t7Jw9KqAHgY0hpQid3se8sXinKdHTGej5DDSrtNTTGWTNi7nzsdlBe6-Y956BVzNgkjV9F423Lt1zIhdhZBrBmwO3dZvtD5dN2nlbR1z_ApBVym0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223029156</pqid></control><display><type>article</type><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</creator><creatorcontrib>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</creatorcontrib><description>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen 1 2 1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway 2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway 3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway 4 Endocrinology Department, Aker University Hospital, Oslo, Norway 5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no Abstract OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration. RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years (range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower limbs was assessed at baseline, after 8 years, and after 18 years. RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude (NAPA) at the last examination were significantly associated with mean HbA 1c ( P &lt; 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P &lt; 0.01). The number of nerves with NCV ( P &lt; 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol, microalbuminuria, or smoking. CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c &lt;8.4% over 18 years was associated with near-normal nerve function. DPN, diabetic polyneuropathy NAPA, nerve action potential amplitude NCV, nerve conduction velocity Footnotes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Accepted April 18, 2003. Received March 6, 2003. DIABETES CARE</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/diacare.26.8.2400</identifier><identifier>PMID: 12882869</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Associated diseases and complications ; Biological and medical sciences ; Blood ; Blood Glucose ; Blood sugar ; Causes of ; Complications and side effects ; Development and progression ; Diabetes ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes. Impaired glucose tolerance ; Diabetic Nephropathies - blood ; Diabetic Nephropathies - diagnosis ; Diabetic Nephropathies - prevention &amp; control ; Diabetic neuropathies ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Female ; Follow-Up Studies ; Glucose ; Glycated Hemoglobin A - analysis ; Humans ; Hyperglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Male ; Measurement ; Medical sciences ; Middle Aged ; Motor Neurons - physiology ; Neural Conduction ; Neurons ; Neurons, Afferent - physiology ; Peroneal Nerve - physiology ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Sural Nerve - physiology ; Type 1 diabetes</subject><ispartof>Diabetes care, 2003-08, Vol.26 (8), p.2400-2404</ispartof><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2003 American Diabetes Association</rights><rights>Copyright American Diabetes Association Aug 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</citedby><cites>FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15003201$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12882869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LARSEN, Jakob R</creatorcontrib><creatorcontrib>SJOHOLM, Hans</creatorcontrib><creatorcontrib>HANSSEN, Kristian F</creatorcontrib><creatorcontrib>SANDVIK, Leiv</creatorcontrib><creatorcontrib>BERG, Tore J</creatorcontrib><creatorcontrib>DAHL-JORGENSEN, Knut</creatorcontrib><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen 1 2 1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway 2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway 3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway 4 Endocrinology Department, Aker University Hospital, Oslo, Norway 5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no Abstract OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration. RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years (range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower limbs was assessed at baseline, after 8 years, and after 18 years. RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude (NAPA) at the last examination were significantly associated with mean HbA 1c ( P &lt; 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P &lt; 0.01). The number of nerves with NCV ( P &lt; 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol, microalbuminuria, or smoking. CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c &lt;8.4% over 18 years was associated with near-normal nerve function. DPN, diabetic polyneuropathy NAPA, nerve action potential amplitude NCV, nerve conduction velocity Footnotes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Accepted April 18, 2003. Received March 6, 2003. DIABETES CARE</description><subject>Adult</subject><subject>Associated diseases and complications</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood Glucose</subject><subject>Blood sugar</subject><subject>Causes of</subject><subject>Complications and side effects</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Nephropathies - blood</subject><subject>Diabetic Nephropathies - diagnosis</subject><subject>Diabetic Nephropathies - prevention &amp; control</subject><subject>Diabetic neuropathies</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Male</subject><subject>Measurement</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Motor Neurons - physiology</subject><subject>Neural Conduction</subject><subject>Neurons</subject><subject>Neurons, Afferent - physiology</subject><subject>Peroneal Nerve - physiology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Sural Nerve - physiology</subject><subject>Type 1 diabetes</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks-KFDEQxoMo7jj6AF4kCHoQesyfTndyXGfdVVjcPayIp5BOV89k6UnGpFvZm2ffwNfzSUw7DQsy5FCh-H31FVWF0HNKVozz-m3rjDURVqxayRUrCXmAFlRxUQhRyodoQWipCqEUO0FPUrolhJSllI_RCWVSMlmpBfp1tR_czvT4XR9Ciy_60YYEeB38EEOPz8bo_AZTib-CiQlfR0gQv0P-QXT7LcQs_TRl8Pno7eCCx87jazM48EPCX9ywxZwc1H9-_p4Kmn9U6PDN3R4wxWfONDBAeooedaZP8GyOS_T5_P3N-kNxeXXxcX16WVhB1FAAa-tKUC46bktmOmFo1aiyYXVHjajLWtJairqqFa1Nw6WlTBnTtq0hTUt4w5fo9aHuPoZvI6RB71yy0PfGQxiTrnkpGMkOS_TyP_A2jNHn3jRjnDBFRZWh4gBtTA_a-S4M0dgN-Gk0wUPncvqUkpoqVcky86sjfH4t7Jw9KqAHgY0hpQid3se8sXinKdHTGej5DDSrtNTTGWTNi7nzsdlBe6-Y956BVzNgkjV9F423Lt1zIhdhZBrBmwO3dZvtD5dN2nlbR1z_ApBVym0</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>LARSEN, Jakob R</creator><creator>SJOHOLM, Hans</creator><creator>HANSSEN, Kristian F</creator><creator>SANDVIK, Leiv</creator><creator>BERG, Tore J</creator><creator>DAHL-JORGENSEN, Knut</creator><general>American Diabetes Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20030801</creationdate><title>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</title><author>LARSEN, Jakob R ; SJOHOLM, Hans ; HANSSEN, Kristian F ; SANDVIK, Leiv ; BERG, Tore J ; DAHL-JORGENSEN, Knut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-e2d765135f3c42af5a16b94b27f1a574781785767917ab38c129aaddda0bd03b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Associated diseases and complications</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood Glucose</topic><topic>Blood sugar</topic><topic>Causes of</topic><topic>Complications and side effects</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Nephropathies - blood</topic><topic>Diabetic Nephropathies - diagnosis</topic><topic>Diabetic Nephropathies - prevention &amp; control</topic><topic>Diabetic neuropathies</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Male</topic><topic>Measurement</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Motor Neurons - physiology</topic><topic>Neural Conduction</topic><topic>Neurons</topic><topic>Neurons, Afferent - physiology</topic><topic>Peroneal Nerve - physiology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Sural Nerve - physiology</topic><topic>Type 1 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LARSEN, Jakob R</creatorcontrib><creatorcontrib>SJOHOLM, Hans</creatorcontrib><creatorcontrib>HANSSEN, Kristian F</creatorcontrib><creatorcontrib>SANDVIK, Leiv</creatorcontrib><creatorcontrib>BERG, Tore J</creatorcontrib><creatorcontrib>DAHL-JORGENSEN, Knut</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LARSEN, Jakob R</au><au>SJOHOLM, Hans</au><au>HANSSEN, Kristian F</au><au>SANDVIK, Leiv</au><au>BERG, Tore J</au><au>DAHL-JORGENSEN, Knut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2003-08-01</date><risdate>2003</risdate><volume>26</volume><issue>8</issue><spage>2400</spage><epage>2404</epage><pages>2400-2404</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes Jakob R. Larsen , MD 1 2 , Hans Sjoholm , MD, PHD 3 , Kristian F. Hanssen , MD, PHD 1 4 , Leiv Sandvik , PHD 5 , Tore J. Berg , MD, PHD 1 4 and Knut Dahl-Jorgensen 1 2 1 Diabetes Research Center, Aker and Ulleval University Hospitals, Oslo, Norway 2 Pediatrics Department, Ulleval University Hospital, Oslo, Norway 3 Neurophysiology Department, Ulleval University Hospital, Oslo, Norway 4 Endocrinology Department, Aker University Hospital, Oslo, Norway 5 Center for Clinical Research, Ulleval University Hospital, Oslo, Norway Address correspondence and reprint requests to Jakob R. Larsen, MD, Departement of Pediatrics, Aker and Ullevaal Diabetes Research Center, Ullevaal University Hospital, Oslo, Norway 0407. E-mail: j.r.larsen{at}ioks.uio.no Abstract OBJECTIVE —To assess the association between 18 years of mean HbA 1c and nerve conduction parameters of the lower limb in patients with type 1 diabetes of 30 years’ duration. RESEARCH DESIGN AND METHODS —HbA 1c has been examined prospectively since 1982 in a group of 39 patients with type 1 diabetes. Mean age at baseline was 25 years (range 18–40) with 12 years’ disease duration. The mean age at diagnosis of diabetes was 12.5 years. Nerve function of lower limbs was assessed at baseline, after 8 years, and after 18 years. RESULTS —A total of 23 men and 16 women were studied. Mean age was 43 years. Mean HbA 1c was 8.2% (range 6.6–11.3) during 18-year follow-up. Nerve conduction velocity (NCV) and nerve action potential amplitude (NAPA) at the last examination were significantly associated with mean HbA 1c ( P &lt; 0. 05). From 1982 to 1999, there was a significant reduction in nerve function in patients with mean HbA 1c ≥8.4% (highest tertile). For example, the mean NCV in the tibial nerve was reduced from 47 to 31 m/s ( P &lt; 0.01). The number of nerves with NCV ( P &lt; 0.01) and NAPA ( P = 0.01) reduced to below the reference level in each patient was also significantly associated to mean HbA 1c . No significant associations were found between nerve function parameters, sex, disease duration, blood pressure, serum cholesterol, microalbuminuria, or smoking. CONCLUSIONS —The present study shows that mean HbA 1c is a strong predictor of nerve function. Mean HbA 1c &lt;8.4% over 18 years was associated with near-normal nerve function. DPN, diabetic polyneuropathy NAPA, nerve action potential amplitude NCV, nerve conduction velocity Footnotes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. Accepted April 18, 2003. Received March 6, 2003. DIABETES CARE</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>12882869</pmid><doi>10.2337/diacare.26.8.2400</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-5992
ispartof Diabetes care, 2003-08, Vol.26 (8), p.2400-2404
issn 0149-5992
1935-5548
language eng
recordid cdi_gale_infotracgeneralonefile_A107199684
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Associated diseases and complications
Biological and medical sciences
Blood
Blood Glucose
Blood sugar
Causes of
Complications and side effects
Development and progression
Diabetes
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - complications
Diabetes Mellitus, Type 1 - drug therapy
Diabetes. Impaired glucose tolerance
Diabetic Nephropathies - blood
Diabetic Nephropathies - diagnosis
Diabetic Nephropathies - prevention & control
Diabetic neuropathies
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Female
Follow-Up Studies
Glucose
Glycated Hemoglobin A - analysis
Humans
Hyperglycemia
Hypoglycemic Agents - therapeutic use
Insulin - therapeutic use
Male
Measurement
Medical sciences
Middle Aged
Motor Neurons - physiology
Neural Conduction
Neurons
Neurons, Afferent - physiology
Peroneal Nerve - physiology
Predictive Value of Tests
Prognosis
Prospective Studies
Sural Nerve - physiology
Type 1 diabetes
title Optimal Blood Glucose Control During 18 Years Preserves Peripheral Nerve Function in Patients With 30 Years’ Duration of Type 1 Diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A43%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20Blood%20Glucose%20Control%20During%2018%20Years%20Preserves%20Peripheral%20Nerve%20Function%20in%20Patients%20With%2030%20Years%E2%80%99%20Duration%20of%20Type%201%20Diabetes&rft.jtitle=Diabetes%20care&rft.au=LARSEN,%20Jakob%20R&rft.date=2003-08-01&rft.volume=26&rft.issue=8&rft.spage=2400&rft.epage=2404&rft.pages=2400-2404&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/diacare.26.8.2400&rft_dat=%3Cgale_proqu%3EA107199684%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223029156&rft_id=info:pmid/12882869&rft_galeid=A107199684&rfr_iscdi=true